-
Britannia Pharmaceuticals: Landmark Apomorphine Study Confirms its Established Role as a Highly Effe
en-cphi.cn
April 26, 2017
Results from the first randomized, controlled trial investigating the efficacy and safety of APO-go?/MOVAPO? (apomorphine) subcutaneous infusion in Parkinson's disease (PD) patients whose motor symptoms are not controlled by other therapies...
-
On the Trail of Parkinson's Disease
dddmag
April 01, 2017
The human brain contains large quantities of the small alpha-synuclein protein. Its exact biological function is still unknown, yet it is closely linked to Parkinson's disease; the protein "clumps together" in the nerve cells of Parkinson patients.
-
FDA clears Newron, Zambon, US WorldMeds' Xadago for Parkinson's disease
firstwordpharma
March 22, 2017
The FDA approved Newron Pharmaceuticals, Zambon and US WorldMeds' Xadago (safinamide) as an add-on therapy to levodopa/carbidopa for patients with Parkinson's disease, the companies announced Tuesday.
-
Acorda's experimental Parkinson's disease drug CVT-301 hits main goal of late-stage trial
firstwordpharma
February 10, 2017
Acorda Therapeutics' experimental drug CVT-301 demonstrated a significant improvement in motor function versus placebo in people with Parkinson's disease experiencing OFF periods in a Phase III study, the company reported.
-
Zambon and Seqirus partner for Parkinson's disease product in Australia and New Zealand
pharmaceutical-technology
January 13, 2017
Italian company Zambon and Australian-based Seqirus have collaborated for Parkinson's disease (PD) product, Xadago, in Australia and New Zealand.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
